RESUMEN
The elucidation of the structure of the antithrombin binding sequence in heparin has given a large impulse to the rational design of heparin related drugs. De novo chemical synthesis of the corresponding pentasaccharide as well as simplified analogues has provided very specific, antithrombin-mediated inhibitors of factor Xa with various pharmacokinetic profiles. Fondaparinux and idraparinux are examples of such compounds that have found clinical application as antithrombotics. Because of the very specific binding to antithrombin the pharmacokinetics of pentasaccharides can be predicted and transferred to other molecules covalently bound to them. The new chemical entities thus obtained display a wide array of antithrombotic activities, giving improved heparin molecules as well as new anticoagulants, devoid of the undesired side effects of heparin and with unprecedented pharmacological profiles. In this context, a direct thrombin inhibitor was covalently coupled to a pentasaccharide by an inert spacer. This compound, EP42675 exerts antithrombin mediated anti-factor Xa activity together with direct thrombin inhibiting capacity. It displays favourable pharmacokinetics as imposed by the pentasaccharide. EP42675 was further modified by the introduction of a biotin moiety in its structure. The new entity obtained, EP217609 exerts the same pharmacological profile as EP42675 and it can be instantaneously neutralised by injection of avidin. Due to this unprecedented mechanism of anticoagulant activity and its ability to be neutralised, EP217609 deserves to be investigated in clinical settings where direct thrombin inhibition is required.
Asunto(s)
Anticoagulantes/farmacología , Biotina/análogos & derivados , Heparina/química , Oligosacáridos/farmacología , Animales , Anticoagulantes/síntesis química , Anticoagulantes/química , Antitrombina III/antagonistas & inhibidores , Antitrombina III/metabolismo , Avidina/farmacología , Sitios de Unión , Biotina/síntesis química , Biotina/química , Biotina/farmacología , Diseño de Fármacos , Inhibidores del Factor Xa , Fondaparinux , Heparina/efectos adversos , Antagonistas de Heparina/química , Antagonistas de Heparina/farmacología , Humanos , Estructura Molecular , Oligosacáridos/síntesis química , Oligosacáridos/química , Polisacáridos/química , Conejos , Relación Estructura-Actividad , Trombosis/tratamiento farmacológico , Trombosis/prevención & controlAsunto(s)
Antitrombina III/química , Insulina de Acción Prolongada/química , Insulina de Acción Prolongada/farmacología , Oligosacáridos/química , Secuencia de Aminoácidos , Animales , Conformación de Carbohidratos , Secuencia de Carbohidratos , Semivida , Insulina de Acción Prolongada/sangre , Masculino , Modelos Moleculares , Datos de Secuencia Molecular , Estructura Terciaria de Proteína , Ratas , Ratas WistarRESUMEN
Despite intense research over the last 10 years, aided by the availability of X-ray structures of enzyme-inhibitor complexes, only very few truly orally active thrombin inhibitors have been found. We conducted a comprehensive study starting with peptide transition state analogues (TSA). Both hydrophobic nonpeptide analogues as well as hydrophilic peptidic analogues were synthesized. The bioavailability in rats and dogs could be drastically altered depending on the overall charge distribution in the molecule. Compound 27, a tripeptide TSA inhibitor of thrombin, showed an oral bioavailability of 32% in rats and 71% in dogs, elimination half-lives being 58 and 108 min, respectively. The thrombin inhibition constant of compound 27 was 1.1 nM, and in an in vivo arterial flow model, the ED(50) was 5.4 nmol/kg.min, comparable to known non-TSA inhibitors. A molecular design was found that combines antithrombotic efficiency with oral bioavailability at low dosages.